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INTRODUCTION 
The role of radiation treatment (RT) in prostate cancer 
has increased in the last decade, since RT achieves a 
similar tumor probability control with a better toxicity 
profile when compared with radical surgery.[1] 
Nowadays, the use of advanced techniques such as 
intensity modulated radiation therapy (IMRT) has 
enabled the delivery highly conformal dose distribution, 
facilitating selective dose escalation while reducing dose 
to organ at risks (OARs) and radiation-induced 
morbidity.[2-3] Nevertheless, the accuracy of planned 
target volume (PTV) localization remains crucial as steep 
dose gradient may increase the risk of geographical miss.     
 
Set-up errors and prostate gland motion relative to the 
pelvic bones are the dominant sources of uncertainty, 
with a range between 4 and 18 mm on day-to-day RT 
fraction.[4-5] 
 
The integration of imaging in RT process has the ability 
to improve daily prostate localization, leading to a more 
precise dose delivery. Several Image-Guided Radiation 
Therapy (IGRT) technologies, such as implanted fiducial 
markers (FM), ultrasound (US), electronic portal 
imaging device (EPID), cone-beam CT (CBCT) and 
megavoltage CT (MVCT) have been employed in 
prostate cancer. 
 
In order to minimize inter-fraction set-up uncertainties 
on-line fiducial-based IGRT, visualized on kV or MV 
images, have been traditionally used for daily image 
guidance and serve as a surrogate for soft tissue target 
volume verification and patient repositioning.[6-7] 
 
Furthermore, implanted intraprostatic gold markers 
improve prostate localization and could allow a reduction 
of PTV safety margins[8-9] with the potential for 
morbidity reduction or late normal tissue toxicities.[10-12] 
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ABSTRACT 
Purpose: The purpose of this work is to assess the consistency of Fiducial Markers (FM) based IGRT in clinical 
practice and the magnitude of daily prostate gland displacements in a subgroup of patients carefully trained to 
maintain a constant and reproducible organ filling. Methods: A physician trained each patient in this selected 55 
patients group, assuring a highly reproducible and well-administered self-preparation. Three FMs were implanted 
using a transrectal ultrasound technique. IGRT was achieved by daily single exposure MV portal images and, every 
6 treatment sessions, double exposure portal images were acquired in order to evaluate differences in displacements 
between fiducial markers and bony structures. Results: There were no grade 3-4 complications (e.g. infections, 
bleeding or abscess) or significant patient reported discomfort related to FM insertion. Differences in 
displacements between FM and bony landmark resulted to be statistically significant (p<0,05), relating to a good 
self preparation. Displacement recorded during first five treatment sessions are not predictive of movement 
directions during remaining fractions. Conclusions: FMs give the opportunity, even in centers not equipped with 
in-room volumetric imaging systems, to perform IGRT. FMs-IGRT in combination to high quality patient rectal 
and bladder preparation allows an improvement of dose delivery and local control while reducing radiotherapy-
related toxicity and overall treatment time. Images control has to be carried out every day in order to be clinically 
useful as displacements occur in random directions. 
 
KEYWORDS: 1. Prostate Cancer, 2. Radiotherapy, 3. Fiducial Markers, 4. Rectal filling, 5. Bladder Filling. 
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Our institution, start up in 2010, initiated transrectal 
fiducial markers insertion for IGRT in 2012 for selected 
low, intermediate and high risk prostate cancer patients 
submitted to radical conformal RT. 
 
Using three implanted gold seeds, the purpose of this 
work, in an academic Department of Radiation Oncology 
not equipped with in-room volumetric imaging systems, 
is to assess the consistency of FMs based IGRT in 
clinical practice and the magnitude of daily prostate 
gland displacements in a subgroup of patients carefully 
trained to maintain a constant and reproducible organ 
filling. 
 
MATERIALS AND METHOD 
Between January 2012 and February 2015, 55 
histologically proven by transrectal ultrasonography 
(TRUS)-guided biopsy localized prostate cancer patients 
who underwent FM placements in our Urological 
Department, were enrolled in this study. 
 
Patients were chosen to take part in a specifically 
designed training course. A physician spent at least 60 
minutes training each patient in this selected group, 
assuring a highly reproducible and well-administered 
self-preparation. The purpose of this careful and highly 
specific training was to ensure the lowest possible organ 
motion between each treatment session. 
 
The clinical characteristics of patients population are 
shown in table 1. Patients were staged according to 7th 
edition (2009) American Joint Committee on Cancer 
staging classification system. Short (6 months) and long 
course (3 years) androgen deprivation therapy was 
performed in intermediate and high-risk cancer, 
respectively.[13]
 
Table 1. Tumor and treatment group characteristics 
Age 
Average 
Range 
73years 
56-79 years 
T stage 
T1 
T2 
T3 
8 
42 
5 
Gleason Score 
6 
7 
8-10 
9 
34 
12 
iPSA 
0-10 
11-20 
>20 
39 
8 
8 
Risk category (D’ Amico) 
Low 
Intermediate 
High 
5 
29 
21 
Dose (Gy) 
72 (2,4 Gy/day) 
78 (2 Gy/day) 
32 
23 
Follow-up since treatment 
completion 
Shorter (<= 12 mo) 
Longer (> 12 mo) 
25 
30 
Androgen deprivation 
Yes 
No 
50 
5 
Technique 
3D 
IMRT 
9 
46 
iPSA = initial PSA, Gy = Gray, 3D = Three Dimensional Radiotherapy, IMRT = 
Intensity-Modulated Radiation Therapy 
 
Informed consent for implant in written form was 
obtained in all patients. 
 
Patients were trained on preparation before FMs implant. 
Antiplatelet therapy is suspended 4 days before till 4 
days after the procedure; antibiotics prophylaxis 
(fluoroquinolone) from the day before to 7 days after 
procedure is prescribed. Patients self-administered an 
enema the evening before and the morning of the 
procedure and, in order to fill the bladder, drank 500ml 
of water 30 minutes before the implant. 
 
Three Qfix RT-4423K-17-3 Knurled Gold Fiducial 
Markers (1.2mm x 3mm in 17 gauge 20cm needles) were 
implanted using transrectal ultrasound guided technique 
in our Urological Department; the three gold markers 
were placed into the prostatic gland to allow 
triangulation and measurement of position in different 
planes (right prostate base, left mid-gland, and right 
apex). Complications occurred following the procedure 
were assessed by a physician. 
 
Starting 3 days before the Computed Tomography (CT) 
scan for planning (AcqSim, Philips, the Netherlands) 
until the RT treatment end, patients adopted diet and 
preparation procedure. In detail, information sheets are 
discussed and handed to patients, reporting instructions 
on how to avoid food with too many fibers or fat, 
flatulent and mass producing; assume every day 2 
charcoal tablet; to empty the rectum before the CT scan 
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and every treatment session with the help of a self-
administered enema.  Patients are trained on how to fill 
the bladder before every RT session with a fluid amount 
based on the volume registered during the planning CT. 
Physicians made sure that every patient fully understood 
procedure. 
 
All patients underwent a planning CT scan in supine 
position using Prostep (ProSTEP™ ABS, 
MEDIZINTECHNIK GMBH) immobilization device, 
filled bladder and empty rectum. The CT and the linear 
accelerator were equipped with identical models of a 
carbon index tables and immobilization devices. The CT 
simulation was performed without contrast medium. CT 
images were acquired with a 5 mm step spaced from L5 
to 3 cm over the first gold seed, 3 mm from 3 cm over 
the first seed to 3 cm under the lowest one, 5 mm until 
the end of testicles. In the eventuality of a non-optimal 
and highly reproducible patient condition, such as an 
insufficient bladder filling or the presence of gas/fecal 
mass in rectum, planning CT was repeated until 
standards were matched. During CT scan was identified, 
using virtual simulation software, the isocenter inside the 
prostatic gland. Three skin tattoos, two laterals and one 
anterior, were carried out for set-up verification by 
alignment to mobile laser system. The CT images were 
transferred to the treatment planning system (Oncentra 
Master Plan v4.3, SP3, Nucletron B.V., Elekta Company, 
The Netherlands) to define the volumes of interest. The 
CTV consisted of the prostate ± seminal vesicles. For 
IGRT technique the PTV was generated by adding 
automatic expansion of CTV of 7 mm in cranio-caudal, 
lateral and anterior directions and 5 mm in posterior 
direction.  
 
Selected Organ at Risks (OARs) were the femoral heads, 
bladder, rectum and penile bulb. Femoral heads were 
contoured from the cranial extremity to the small 
trochanter, including the femoral neck; penile bulb, 
bladder and rectum were outlined entirely. FMs were 
also contoured. 
 
During the implementation phase, as staff completed the 
learning curve, first 9 patients out of 55 included in this 
study, were treated with 3D technique while the 
remaining 46 patients underwent IMRT-planned 
treatment.  In 23 patients total radiation dose was 78 Gy 
with conventional fractionation schedule while in 32 
cases IMRT was performed with moderate 
hypofractionation schedule (table 1). 
 
Patients were treated with 3D technique using 5 
individually shaped coplanar fields (gantry angle 0°, 45°, 
90°, 270°, 315°) delivered with 10 or 18 MV beam 
photons energy produced by a linear accelerator 
(Synergy Platform; Elekta Atlanta, GA, USA) in daily 
fractions of 2 Gy. 
  
In IMRT technique (Figure 1), all patients were treated 
with equally spaced 7-9 coplanar beams arrangement 
(7F-IMRT), 10 MV beam energy and direct Step & 
Shoot modality. Dose calculation was performed with 
the Plan Optimization Module (Raysearch Laboratories, 
Sweden) of our TPS. The dose was prescribed at the 
ICRU point. The optimization settings had the goal of 
covering greater than 95% of the PTV volume with the 
95% of prescription dose limiting hotspots to 107% of 
the prescription dose. Collapsed-cone convolution 
methods were employed for final dose calculations. 
 
To minimize the risk of gastrointestinal (GI) and 
genitourinary (GU) toxicities, QUANTEC (2010) dose-
volume constraints were applied.[14] 
 
 
Figure 1. IMRT technique 
 
     
Figure 2A. DPI 0° 
 
 
Figure 2B. DPI 90° 
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Figure 3A. DRR 0° 
 
   
Figure 3B. DRR 90° 
 
Starting from first RT fraction, before every single 
session, two orthogonal (0° and 90°) megavoltage Digital 
Portal Images (DPI) were acquired (Figures 2A-2B) 
using an electronic portal imaging device (EPID). 
 
Daily single exposure DPI were obtained using 6MV 
photons beam with a field size of 10x10 cm and 
superimposed with the reference images (Digitally 
Reconstructed Radiograph, DRR) generated from the 
Treatment Planning System (TPS) (Figures 3A-3B) 
while every 6 treatment sessions, double exposure DPI 
images (20x20 cm field size) were acquired.  
 
With the use of an I-VIEW system (Elekta Atlanta, GA, 
USA), a comparison between gold seeds position on DPI 
and DRR was carried out. Taking into account system’s 
sensitiveness, we established a 3 mm threshold for table 
position correction.  
 
Acute radiation toxicities were assessed weekly using 
RTOG/EORTC scoring system.  
 
Differences in mean between seeds and bone 
structures movements along cranio-caudal, lateral and 
anterior directions were compared using two-sided t-
test. One-sample t-test was used for comparison of 
movements of seed between each other. Computations 
were performed with the STATA statistical package, 
release 13.1 (STATA Corp, College Station, TX). All p 
values were two-sided, and p< 0.05 was considered 
statistically significant. 
 
RESULTS 
None severe FM implants related complications such as 
infections, bleeding or abscess were reported. Minor 
rectal bleeding, dysuria or hematuria affected less than 
10% of implanted patients and were self limiting. 
Patients reported that discomfort related to implant 
procedure has been inferior to standard diagnostic 12-
core biopsy. 
 
GI and GU high grade toxicity (>G2) were 5.45% and 
1.82%, respectively. Results are shown in table 2.  
 
Table 2. Acute toxicity in treatment group. 
ACUTE TOXICITY 
 GI GU 
G0 22 12 
G1 22 28 
G2 8 14 
G3 3 1 
G4 0 0 
TOTAL 55 55 
RTOG/EORTC scoring system. GI=gastro-
intestinal; GU=genito-urinary 
 
A total of 4214 (3714 regarding seeds and 500 of bony 
structures) DPI were acquired during this study. Due to 
technical reasons 32 images related to FMs were 
excluded from the analysis. Acquisition and matching of 
daily DPI-DRR increased the overall treatment time of 
about 5 minutes per patient. 
 
Patients positioning has been corrected, according to 
FMs, 1533 times out of 1857 total treatment sessions. 
 
In Figure 4 is shown the box plot of seeds and bones in 
latero-lateral and craniocaudal directions at 0°. The mean 
value and standard deviation of seeds movement in 
latero-lateral direction is found to be – 0,81 ±  3,3 mm; 
meanwhile mean value and standard deviation of bony 
structure is 1,3 ± 3,3 mm. The found difference, despite 
being little, is statistically significant (t-Student p=0,03). 
 
In the same way considering cranio-caudal direction, 
mean value and standard deviation turned out to be 0,5 ± 
3,9 mm for seeds and -0,18 ± 2,9 mm for bones; even in 
this case, despite being less than a millimeter, results are 
statistically significant (t-Student p=0,01). 
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Figure 4. Seeds and bones shifts in CC and LL 
directions at 0° 
 
 
Figure 5. Seeds and bones shifts in AP and CC 
directions at 90° 
 
 
Similarly in Figure 5, box plot of movements in antero-
posterior and cranio-caudal directions, in relation to 90° 
projection, is displayed. In detail, in antero-posterior 
direction mean value and standard deviation appeared to 
be 1,7 ± 5,3 mm when considering seeds movement and 
0,8 ± 4,1 mm for bony structures; also in this case 
difference reaches statistical significance (t-Student 
p=0,01), even if limited. 
 
In cranio-caudal direction mean value and standard 
deviation result to be 0,44 ± 3,9mm and -0,64 ± 2,9mm 
for seeds and bones respectively; results are statistically 
significant in this case as well (t-Student p=0,01). 
 
In table 3 are shown shift percentages based on FM 
displacements and grouped by dimension. The vast 
majority of target movements resulted to be inferior to 5 
millimeters. The worst-case scenario involves the AP 
dimension at 90° angle. 
 
 
 
 
 
 
 
 
Table 3. Shifts percentages grouped by proportion of displacements.  
Dimension 
Proportion of 
displacements 
<3 mm (%) 
Proportion of 
displacements 
<5 mm (%) 
Proportion of 
displacements <7 
mm (%) 
Median in 
absolute value 
(mm) 
LL 0° angle 64,6 85,9 95 2 
CC 0° angle 57,8 78,6 90,4 2,25 
AP 90° angle 41,2 65,5 80,9 3,5 
CC 90° angle 57,6 79,4 91,5 2,35 
LL = latero-lateral, CC = cranio-caudal, AP = antero-posterior 
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In Figure 6 are shown results from the analysis between 
FMs movements during first five treatment session and 
movements registered during the entire treatment course. 
Considering latero-lateral and antero-posterior directions, 
results did not reach statistical significance (p=0,87 and 
p=0,95, respectively). Regarding cranio-caudal direction, 
found difference is instead statistically significant 
(p=0,01). 
 
 
Figure 6. Movement recorded during first five 
treatment session compared to movements recorded 
during whole treatment course 
 
DISCUSSION 
Radiotherapy has benefited from great technical advance 
during last years. IGRT is now approaching routine use, 
as it basically increases the therapeutic ratio by reducing 
the CTV-PTV margins.[15] A successful radiation 
treatment relies on a precise dose delivery to the target 
allowing for dose escalation, while sparing normal 
surrounding tissues. 
 
Accurate target localization remains a crucial factor in 
order to grant a high precision treatment and lower the 
risk of generating geographical misses. Interfraction and 
intrafraction target movements are contributing factors to 
both random and systematic errors and can be partially 
corrected with the introduction of daily image guidance 
or tumor tracking.  
 
A widely accepted and cost-effective method to improve 
prostate localization before each treatment session, is the 
use of implanted FMs, alone in a department not 
equipped with onboard imaging, or combined with other 
image guidance technique.[16-17] 
 
We did not detect any major complication derived from 
FM’s implant; no clinically relevant short and long term 
changes were reported in QoL due to FMs implantation. 
Even if some authors choose not to discontinue 
antiplatelet therapy[18-20] we maintained the withdrawal 
of antiplatelet drugs considering it simpler and safer to 
apply. In the same way we choose to maintain the 
antibiotics prophylaxis in consideration of transrectal 
implant procedure in order to minimize possible 
complications rate.[21] 
 
In our study, IGRT was achieved by daily online 
verification of gold seeds in the prostate gland, analyzing 
orthogonal DPI. To determine FMs position patients 
received every day 6 Monitor Unit (MU), resulting in a 
total administered dose to PTV on each day of 4,26 cGy. 
Kan et al.[22] reported that each standard mode pelvis 
Cone Beam Computed Tomography (CBTC) had an 
effective dose of 22,7 mSv and daily usage can deliver a 
substantial amount of dose to critical organs; small 
bowel and rectum can receive an additional dose up to 
1.4 to 2.2 Gy in 35 fractions and increase the effective 
dose of circa 800 mSv, which could induce an additional 
secondary cancer risk of 4%. 
 
As a part of internal quality assurance protocol, we 
evaluated the stability of knurled gold seeds in 10 
patients by measuring on weekly CT scans the distance 
between each marker (Inter-marker distance). The 
recorded unpublished data showed neither statistically 
significant marker displacement nor seed loss, justifying 
the routinely use of these type of FMs. All that 
considered we can uphold that US guided FMs implant, 
in terms of implant-related morbidity, is a feasible and 
safe procedure, as it already was demonstrated by many 
studies.[23-24] 
 
In our opinion, FMs give the opportunity to carry out a 
moderate hypofractionation schedule with a substantial 
reduction of overall treatment time and a relevant 
enhancement in dose delivery precision by the use of an 
highly conformal dose distribution technique. 
 
Considering that prostatic gland has no link to bony 
structures, its position mainly depends to surrounding 
organs; greater part of this position is determined by 
bowel and rectum filling. 
 
The aim of this study was to analyze if maintaining a 
reproducible filling of said organs could reduce gland 
motions, giving the opportunity to reduce treatment 
margins. FMs position, acting as surrogate of prostate 
localization, is determined either by daily set-up and 
surrounding organs filling, while bony landmarks 
represent set-up only. Every patient resulted to be 
capable of carrying out a good self preparation, in order 
to keep under control organs filling and consequently the 
preparation level each patient underwent 2 CT scan 
during treatment course, bladder filling resulted to be 
constant during treatment in contrast to what found by 
other authors.[25] Our rectal preparation protocol was well 
tolerated in accordance to other publications.[26] 
 
Results shown in Table 3, suggest that even if a good 
preparation is carried out, the rectal volume affects 
considerably the position of prostate. 
 
Patients positioning has been corrected, according to 
daily FMs position, 1533 times out of 1857 total 
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treatment sessions with a cut-off in shift in order to 
correct patient’s position settled to 3 mm, in other terms 
FMs were useful in determining patient set-up in 83% of 
treatment sessions. Set-up and organ position data 
obtained from FMs and from bony structures images 
differ more than 3 mm in at least one projection in 66% 
of times and in 26,4% of times for more than 6 mm. 
 
Treatment margins were set to 7 mm in isotropic except 
5 mm at prostate-rectal interface as IGRT with grossly 
reduced margins was found out to be a predictor of 
poorer biochemical outcome, leading to recurrence in 
42% vs 9% in non IGRT patients at 5 years.[27] 
 
Some studies demonstrated that the accuracy of FMs, 
compared to other guidance technique, did not differ 
more than 3-4 mm underlining the good organ 
localization FMs can provide, especially with the use of 
kV imaging.[28-29] Unfortunately, in our Department kV 
image is not available, and daily DPI are acquired with 
the primary MV photons beam that are lower in quality 
and more troublesome to interpret. Gill et al.[30] reported 
that if a 3 mm threshold were to be applied to both EPI 
and KVI (kV Imaging) units, there would still be 27% 
more actual couch shifts on KVI units than on EPI units. 
Pisani et al.[31] studied the interobserver alignment of an 
anthomorphic phantom with a known translational shift 
when imaged with both kV and MV beams; they found 
that interobserver alignment was more variable with 
megavoltage imaging than KVI. Even if EPI are 
objectively less accurate than KVI, the reported 
differences in median absolute displacement between the 
two technologies is no more than 1 mm, validating EPI 
as an accurate tool for IGRT in prostate cancer 
patients.[29] When operating the choice of margins 
extension, rapid intrafractional movements must be kept 
in consideration. Intrafraction motion of prostate have 
been investigated in various series, standard deviation 
are quite comparable ranging around 1 mm in LR 
directions and 3 mm in SI or AP direction.[32] The 
LINAC available in our Department doesn’t provide any 
automated couch shift, correction of patient position is 
carried out manually by technicians, that increases  both 
residual treatment error and treatment time with an added 
risk of patient movement.[33] 
 
Differences in shift measured between gold seed and 
bony structures turned out to be statistically significant 
despite being little in value; those results can be referred 
to a well controlled organ motion, tiny differences in 
displacement can relate to constant surrounding organs 
filling and therefore to a good patients self-
preparation.[34] 
 
Constant organ filling can also be related to low 
treatment toxicity levels, in more detail acute 
RTOG/EORTC GI and GU score higher than G2 has 
been reported in only 5.45% and 1.82%, respectively. 45 
out of 55 patients underwent a follow-up prolonged 
enough (>6 months) to assess late treatment toxicity, 
only 1 (2,22%) high grade (>G2) has been reported 
referring to GU symptoms and none (0%) GI. 
 
Even if organ shifts are kept low, their path cannot be 
foreseen because it occurs in random directions, that 
considered portal imaging has to be carried out every 
day, this causes a slight increase in treatment session 
time, we however quantified that time consumption in no 
more than 5 minutes.  
 
Data collected therefore suggest that constant organ 
filling cannot replace FM based image guidance. The use 
of highly conformal volumes made possible by IMRT 
requires, in our opinion, a precise knowledge of target 
position, otherwise risk of causing high toxicity by 
missing treatment target is substantial. 
 
CONCLUSIONS 
Fiducial Markers based IGRT-IMRT allows the 
localization of the prostate gland during radiotherapy. 
Implant procedure is a simple, safe and well tolerated 
technique, severe complications are uncommon and 
marker migration is not clinically significant.  
 
High quality self preparation can reduce prostate 
displacement, but cannot substitute the accuracy of target 
localization given by daily image guidance. Images 
control has to be carried out every day in order to be 
clinically useful as displacements occur in random 
directions. 
 
Finally, as high dose gradient technique and 
hypofractionation schedule requires an accurate daily 
target localization, in our opinion the implementation of 
Fiducial based IGRT can, in a cost-effective way, 
improve dose delivery in a Department of Radiation 
Oncology not equipped with in-room volumetric imaging 
systems.  
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